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Abstract
Background: Heart failure (HF) patients discharged from rural hospitals have higher 30-day readmission rates.
Self-management (SM) reduces readmissions, but adherence to SM guidelines is low in the rural HF population.
We tested a home-based intervention to enhance patient activation and lead to improved SM adherence.
Methods: In this two-group, repeated measures randomized control trial, the main outcomes were patient
reported and clinical outcomes associated with SM adherence, and all-cause readmission at 30, 90 and 180 days.
Results: The study included 100 HF patients discharged from a rural critical access hospital. The intervention group
received a 12-week SM training and coaching program delivered by telephone and tailored on subjects’ activation
levels. At α = .10, the PATCH intervention showed significantly greater improvement compared to usual care in
patient-reported SM adherence: weighing themselves, following a low-sodium diet, taking prescribed medication,
and exercising daily (all p < .0005) at 3 and 6 months after discharge. In contrast, groups did not differ in physical
activity assessed by actigraphy or in clinical biomarkers. Contrary to expectation, the 30-day readmission rate
was significantly higher (p = .088) in the intervention group (19.6 %) than in the control group (6.1 %), with
no differences at 90 or 180 days.
Conclusion: It is feasible to conduct a randomized controlled trial in HF patients discharged from rural critical
access hospitals. Significantly higher patient-reported SM adherence was not accompanied by lower clinical
biomarkers or readmission rates. Further research is needed to understand mechanisms that influence outcomes and
healthcare utilization in this population.
Trial registration: Clinical Trial Registration Information: ClinicalTrials.gov; NCT01964053.
Abbreviations: AHFKT-V2, Atlanta heart failure knowledge test-version 2; BNP, B-type natriuretic peptide; CAH, Critical
access hospital; ED, Emergency department; HF, Heart failure; Na/Cr, Urine sodium/creatinine ratio; PAM, Patient
activation measure; PATCH, Patient AcTivated Care at Home; RSCB, Revised self-care behavior.; SM, Self-management;
UC, Usual care
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Background
Compared to their urban counterparts, HF patients dis-
charged from rural hospitals, primarily critical access
hospitals (CAHs), have higher 30-day readmission [1].
Failing to adhere to self-management (SM) guidelines
accounted for 50 % of hospital readmissions in HF
patients [2]. SM adherence involves engaging in recom-
mended SM behaviors such as monitoring daily weight,
following a restricted sodium diet, taking medication as
prescribed, exercising regularly, and keeping follow-up
appointments [3].
To date, most strategies promoting SM adherence
were developed and tested in urban health centers [4].
Less is known about these interventions’ feasibility and
efficacy in rural areas where resources such as HF spe-
cialists and multidisciplinary HF management teams are
often limited [5]. Further, rural patients may have lower
self-management knowledge and health literacy [5], lack
of HF-specific SM education and counselling from pro-
viders [6], and lack of SM support [7]. Consequently,
rural HF patients tend to exhibit low SM adherence [5].
Past research also has been limited by lack of a theoretical
framework [8], unclear mechanism of the intervention [9],
and lack of objective measures of SM adherence [10].
To address the knowledge gap, we conducted a ran-
domized controlled trial to test an activation-enhancing
intervention to improve SM adherence. Patient activa-
tion is defined by Hibbard as the person’s readiness, will-
ingness, and ability to manage his/her own health and
healthcare [11]. We hypothesized that the HF patient
with higher activation will have greater SM adherence.
The purpose of this study is to examine the effects of a
12-week patient activation intervention (Patient AcTi-
vated Care at Home [PATCH]) on the improvement of
SM adherence and its health outcome (i.e., hospital
readmission) in HF patients following discharge from
CAHs.
This study had the following specific aims:
Aim 1. To evaluate the immediate (3 months) and
extended effects (6 months) of the patient activation
intervention on SM adherence.
Aim 2. To evaluate the effects of the patient activation
intervention on hospital readmission and emergency
department (ED) visit rates at 30 days, 3 and 6 months.
Aim 3. To evaluate the mechanism of the patient
activation intervention, comparing the intervention and
usual care (UC) groups on SM knowledge, self-efficacy
for SM, patient activation, and SM strategies at the end
of intervention.
Conceptual framework
To guide the PATCH intervention, we developed a con-
ceptual framework based on components of Lorig’s
chronic disease self-management model [12], Hibbard’s pa-
tient activation theory [13], and Bandura’s conceptualization
of self-efficacy [14]. The mechanism of intervention is to
improve HF patients’ SM adherence by helping them
advance through four activation levels: 1) starting to take a
SM role; 2) building SM knowledge, skills and confidence;
3) taking SM actions; and 4) maintaining SM behaviors.
The central hypothesis is that HF patients with higher levels
of activation will be more likely to engage in SM behaviors,




This was a two-group, repeated measures, randomized
controlled trial. The study is registered on the Clinical
Trial website (NCT01964053). The study protocol was
approved by the University of Nebraska Medical Center
Institutional Review Board and rural hospital ethics
committee. All participants gave written informed con-
sent. Detailed information has appeared in a previously
published study protocol [16].
Study setting
The study was conducted between September 2013
and October 2015 at a rural critical access hospital
(CAH). To reduce the financial vulnerability of rural
hospitals and improve rural residents’ healthcare ac-
cess, Centers for Medicare and Medicaid Services
(CMS) created a “Critical Access Hospitals (CAHs)”
designation based on the 1997 Balanced Budget Act.
A certified rural CAH must have less than 25 acute
care inpatient beds and be located more than 35
miles from another hospital [17].
Patient inclusion and exclusion
The principal investigator and research assistants who
have ethical access at the study site were responsible for
identifying potential subjects, screening for eligibility
and recruitment. Eligible subjects: 1) were 21 or older;
2) had HF as one of their discharge diagnoses; 3) had
New York Heart Association (NYHA) class II to IV
symptoms or NYHA class I symptoms and at least one
other HF-related hospitalization or ED visit in the previ-
ous year; 4) were discharged to home; 5) passed a mini-
cog screen;[18] 6) understood English; and 7) had access
to a phone. Patients were not eligible if they had: 1)
scheduled procedures/surgeries during hospitalization;
2) depressive symptoms indicated by a score ≥ 3 on the
Patient Health Questionnaire-2 (PHQ-2);[19] 3) docu-
mented diagnostic evidence of liver cirrhosis; or 4) renal
failure (serum creatinine greater than 2.0 mg/dl).
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Intervention and usual care
Subjects randomized to the Control Group received only
usual care, the standard discharge teaching for HF that
includes written and verbal information about HF self-
care and scheduled follow-up doctor appointments.
Subjects randomized to the Intervention Group received
both usual care and the 12-week PATCH intervention.
The intervention was comprised of two phases: a one-
on-one in-hospital SM training session and post-
discharge reinforcement sessions (twice a week for the
first 2 weeks, once a week for weeks 3–6, and every
other week for weeks 7–12) delivered by telephone.
Intervention content was presented in a variety of for-
mats (e.g., verbal, written, visual) with interactive ability.
Besides SM workbooks, each subject was provided an
SM toolkit, including a calendar for weight and salt daily
logging, a step-on weight scale with large and bright
readings, and an electronic pill organizer reminder
alarm. Each intervention session lasted about 45–
50 min. Booster sessions were administered to subjects
struggling with SM at home. Subjects received the tai-
lored intervention sessions based on activation level,
pre-set goals, and specific SM needs. Intervention details
were reported in another publication [16].
Outcome measures
Baseline data collection occurred prior to hospital dis-
charge and at 3 and 6 months after discharge. The pri-
mary outcomes measured at all three times were: SM
adherence (self-reported frequencies of daily weighing,
following a low-sodium diet, taking prescribed medica-
tions, exercising, and attending follow-up appoint-
ments), clinical biomarkers (B-type natriuretic peptide
[BNP] and urine sodium/creatinine ratio [Na/Cr]), and
all-cause readmissions and ED visits measured at 30, 90
and 180 days. To assess baseline SM adherence, we
asked the participants to recall specific SM behaviors in
the past 12 months. The healthcare utilization data were
collected from both self-report and primary care pro-
vider records. In addition to self-report measures,
objective measures of physical activity were obtained
using an accelerometer that subjects were asked to wear
for 7 consecutive days at each assessment period.
The secondary outcomes were measured via question-
naire at baseline and 3 months to test the intervention
mechanisms, including SM knowledge, self-efficacy for
SM, patient activation, and SM strategies. Details about
measures, instruments and their psychometric properties
were reported in another publications [16, 20, 21].
Randomization, blinding and allocation concealment
Given the nature of the treatment, blinding of either
subject or interventionist was impossible, but the data
collector was blinded to treatment assignment. The
project statistician used an on-line pseudo-random num-
ber generator to create an allocation schedule; random
ordering of block sizes four and six was used to main-
tain even accrual through the study. Group assignments
were placed in sealed envelopes and opened sequentially
as patients were enrolled.
Sample size and statistical analysis
The required sample size was estimated using two-sided
tests and α = .10. A liberal alpha was chosen to minimize
the likelihood of overlooking promising effects in this
preliminary study. For a moderate effect size (Cohen’s
f = .25), 41 per group provided power of .80 for the
test of the mean group difference over time. It pro-
vided similar power for a z-test of the difference in
group proportions of at least .25. A target sample size
of 100 patients allowed for up to 20 % attrition. Fur-
ther details may be found in Young et al. [16].
For the continuous outcomes in Aim 1 (e.g., physical
activity outcomes and level of BNP and urine Na/Cr),
linear mixed model methods were used to compare the
groups across the 6-month period, adjusting for baseline
levels on the respective outcome, with tests of the differ-
ence in estimated marginal means (Group effect) and
whether change from 3 to 6 months differed in the
groups (Group X Time effect). These methods allow for
inclusion of partial cases (missing either month 3 or
month 6 follow-up data) and for flexible specification of
the covariance structure of repeated measurements.
However, cases missing on covariates or having only co-
variate (baseline) measures cannot be included.
Distributions of adherence outcomes measured as
number of days per week were clearly non-normal, so
responses to those questions also were categorized as
non-adherent (0 days), partially adherent (1–6 days), or
adherent (7 days), and groups compared using χ2. For
outcomes having adherence guidelines (e.g., weighing),
patients also were classified as being adherent or not
and group differences in the proportion of adherent
patients at the end of the intervention (3 months) and at
6 months were tested using χ2.
To evaluate immediate and extended effects of the
intervention on rehospitalization and ED visits (Aim 2),
a χ2 test was used to compare group proportions separ-
ately at 30 days, 3, and 6 months.
To evaluate the mechanism of the patient activation
intervention (Aim 3), an independent t-test was used to
compare the groups on average change in intervention
components from baseline to 3 months after hospital
discharge. These tests were one-tailed to correspond to
the hypothesis that the PATCH intervention would in-
crease SM knowledge, self-efficacy, activation levels, and
use of SM strategies.
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Effect sizes were also estimated for the estimated mar-
ginal mean difference between groups. There is no
established method of estimating effect sizes in linear
mixed models, so standardization (d = |M1 – M2| / SD)
was carried out using the baseline standard deviation of
the outcome, pooled across groups. For variables having
no baseline measurement, the standard deviation from
the control group at 3 months was used. For tests of
intervention components, the group difference in mean
change was standardized using a pooled standard devi-
ation of the change scores.
Results
Between September 2013 and October 2015, 629 poten-
tially eligible candidates were screened. Of these, 524
subjects were excluded because of 1) failing to meet the
screening criteria; 2) declining participation; 3) being
transferred to another facility during hospital stay; 4)
deteriorated health conditions; or 5) less than 24-h
length of stay, which made it impractical to conduct
Phase I intervention and baseline data collection. After
randomization, three subjects were excluded from the
PATCH intervention group and two from the control
group as described in the CONSORT study flow diagram
(Fig. 1). A sample of 100 HF subjects (PATCH = 51, con-
trol = 49) entered the final analysis.
Sample characteristics
The 64 females and 36 males ranged in age from 40 to
93, with a mean of 70.2 (±12.2) years. On average, they
had 12.9 (±2.3) years of education and a median annual
household income of $20,000–29,000. Most were NYHA
Excluded (n= 524)
Failed the screening tools (n= 313)
Declined to participate (n= 154)
Transferred to another facility (n = 30)
Deteriorating Health condition (n= 11)
Time restriction (n = 16)
Analysed (n= 51)
Excluded from analysis (give reasons) (n= 0)
Three Month Post Discharge Data Collection
Lost to follow-up (n= 0)
Discontinued intervention (n= 0)
Three Month Post Discharge Data Collection
Lost to follow-up 
Dropped out following baseline (n= 1)
Deceased after baseline (n = 1)
Allocated to control group (n=51)
Received standard discharge teaching 
(n = 51)
Did not receive standard discharge teaching 
(n = 0)
Analysed (n= 49) 
Excluded from analysis (n=0)
Allocation
Analysis
Received Phase 2 intervention delivered by 
12-week follow-up phone calls (n = 51)
Did not receive Phase 2 intervention
Dropped out following discharge (n= 1)
Deceased after discharge (n = 1)
Follow-Up
Randomized (n= 105)
Assessed for eligibility (n=629)
Allocated to intervention (n= 54)
Received Phase 1* intervention (n=51 )
Did not receive intervention
Dropped out following consent: (n=1)
Six Month Post Discharge Data Collection
Lost to follow-up (n= 0)
Discontinued intervention (n= 0)
Six Month Post Discharge Data Collection
Lost to follow-up (n= 0)
Discontinued intervention (n= 0)
Enrollment
Fig. 1 Study flow diagram
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level II (49 %) or III (42 %) with preserved ejection frac-
tion (55.7 ± 11.1). On average, patients had eight (±2.6)
comorbidities, with the overwhelming majority having
hypertension (99 %), coronary artery disease (94 %),
arthritis or degenerative joint disease (89 %), and hyper-
cholesterolemia (84 %). Subjects reported having an
average of 12.3 (±6.0) prescriptions, requiring 16.2 (±8.8)
pills per day (Table 1). At hospital discharge, 50 % of the
subjects were prescribed beta blockers and 52 % either
ACE inhibitors or angiotensin receptor blockers.
The PATCH intervention and control groups were
comparable on all demographic and baseline clinical
characteristics with a few exceptions. A detailed break-
down is presented in Table 1. There were more females
in the control group (75.5 %) than in the intervention
group (52.9 %); only 38.8 % were married or partnered
in the control group compared to 60.8 % in the interven-
tion group. Those randomized to the intervention group
had lower cardiac function than those in control group.
Compared to subjects in the control group (26.5 %),
more than twice as many subjects (56.9 %) in the inter-
vention group were NYHA class III with ejection frac-
tion less than 50 (23.5 % in PATCH group vs. 8.2 % in
control group).
At baseline, the majority of subjects had low activation
in terms of SM adherence. Patient activation measure
(PAM) scores placed 39 % of subjects in activation level
1 (starting to take a role), 23 % in level 2 (building
knowledge, skills and confidence), 18 % in level 3 (taking
action), and 19 % in level 4 (maintaining behaviors).
Aim 1. To evaluate the immediate and extended effects
of the patient activation intervention on SM adherence.
Descriptive statistics for SM adherence outcomes and
the results of the statistical tests from fitting a linear
mixed model are presented in Table 2. None of the tests
of Group x Time interaction were significant. Those
receiving the PATCH intervention had significantly higher
self-reported adherence to SM behaviors, including
average days per week weighing themselves (p < .0005; d =
1.1), following a low-sodium diet (p < .0005; d = .9), and
exercising (p < .0005; d = .6). The intervention group also
reported significantly fewer days missing any doses of pre-
scribed medication (p = .030; d = .6) (Table 2). Approxi-
mately twice as many patients in the intervention group
as in the control group reported that they carried out
these behaviors 7 days a week. Details of the frequencies
of SM adherence for these outcomes at 3 and 6 months
are displayed in Table 3. In the intervention group,
approximately 84 % at 3 months and 86 % at 6 months
reported not missing any doses in the previous week com-
pared to 68 % at both times in the control group. Nearly
all subjects (100 % of the PATCH group, 98 % of the
Table 1 Patient demographic and clinical characteristics
All (n =100) Intervention




Age (years) 70.2 ± 12.2 68.7 ± 11.8 71.8 ± 12.6
Male 36 (36) 24 (47.1) 12 (24.5)
Education (years) 12.9 ± 2.3 13 ± 2.4 12.8 ± 2.1
Caucasian 95 (95) 48 (94.1) 47 (95.9)
Married/living with partner 50 (50) 31 (60.8) 19 (38.8)
Currently employed outside
home
29 (29) 16 (30.8) 13 (26.5)
Annual family income (< $30,000) 51 (51) 24 (47.10) 27 (55.1)
Risk factor profile
Body Mass Index (kg/m2) 32.3 ± 7.1 33.4 ± 7.4 31.2 ± 6.8
Clinical data
Number of comorbidities 8 ± 2.6 7.8 ± 2.5 8.0 ± 2.7
1.Hypertension 99 (99) 51 (100.0) 48 (98.0)
2.Coronary artery disease 94 (94) 46 (90.2) 48 (98)
3.Arthritis degenerative joint
disease
89 (89) 43 (84.3) 44 (89.8)
4.Hypercholesterolemia 84 (84) 43 (84.3) 41 (83.7)
5.Diabetes mellitus with or
without complications
41 (41) 41 (80.4) 33 (67.4)
6.Dyspepsia 50 (50) 24 (47.1) 26 (53.1)
7.Peripheral vascular disease
or lower extremity edema
45 (45) 22 (43.1) 23 (46.9)
8.Chronic obstructive
pulmonary disease
38 (38) 22 (43.1) 16 (32.7)
9.Chronic renal disease 23 (23) 12 (23.5) 11 (22.4)
Number of medications
taking per day
16.2 (±8.8) 16.4 ± 10.0 15.9 ± 7.4
Beta blockers 50 (50) 27 (52.9) 23 (46.9)
ACE inhibitors 35 (35) 16 (31.4) 19 (38.8)
Angiotensin receptor blocker 18 (18) 8 (15.7) 10 (20.4)
Previous hospitalizations
within 1 year (≥1)
43 (43) 22 (43.2) 21 (42.8)
Previous ED visits within
1 year (≥1)
60 (60) 30 (58.9) 30 (61.2)
Cardiac function
Functional class (NYHA)
•II 49 (49) 15 (29.4) 34 (69.4)
•III 42 (42) 29 (56.9) 13 (26.5)
Ejection fractiona 55.7 ± 11.1 53.4 ± 12.9 58.3 ± 8.1
Ejection fraction < 50 %a 16 (16) 12 (23.5) 4 (8.2)
Main outcome: Patient Activation Measure (PAM) level
1.Starting to take a role 39 (39) 19 (37.3) 20 (40.8)
2.Building knowledge, skills
and confidence
23 (23) 9 (17.6) 14 (28.6)
3.Taking action 18 (18) 13 (25.5) 5 (10.2)
4.Maintaining behaviors 19 (19) 10 (19.6) 9 (18.4)
Results are presented as mean ± SD or n (%)
aEjection fraction was available for n = 47 in the intervention group, n = 41 in
the usual care group. Percentages include cases with missing data in
the denominator
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control group) attended the scheduled follow-up appoint-
ment with their primary care provider within 30 days of
discharge.
In contrast to the self-report measures, there were no
significant group differences in the estimated mean
activity counts, energy expenditure, or minutes in
moderate or more intense activity, with small effect
sizes (d = .03 to d = .05). Results from a supplemental
analysis of the actigraphy variables that treated base-
line as a time point in order to include all partial
cases were consistent with these findings, with no
significant differences between groups in the pattern
of change across time on any of the actigraphy vari-
ables (p-values ranged from .589 to .858 for the tests
of Group X Time interactions). B-type natriuretic
peptide (BNP) was log-transformed due to strong
positive skewness. Neither log- transformed BNP nor
estimated daily sodium intake based on the urine test
differed significantly in the two groups. There were
also no significant group differences in the proportion
meeting SM adherence criteria of ≤ 1500 mg of
sodium daily and of ≥ 120 min per week of moderate
or higher intensity activity (adherence defined as
80 % of the recommended 150 min per week), either
at the end of the intervention (3 months) or at the 6-
month follow up. Few patients in either group met
these criteria at any point in the study (Table 3).
Aim 2. To evaluate the effects of the patient activation
intervention on hospital readmission and ED rates at
30 days, 3 and 6 months.
Contrary to expectation, the 30-day hospital readmis-
sion rate was significantly higher (χ2 with continuity cor-
rection = 2.914, p = .088) in the PATCH group (n = 10,
19.6 %) than in the control group (n = 3, 6.1 %). At
Table 2 Self-management adherence outcomes by group and time









means [95 % CI]
3 months 6 months
Adherence to self-management behaviors per self-report
Days per week
weigh self
Intervention 4.8 ± 2.7 4.6 ± 2.4 4.7 ± 0.3 <.0005 .687 2.98 [2.10, 3.86]
Control 1.9 ± 2.7 1.5 ± 2.5 1.7 ± 0.3
Days per week follow
low-sodium diet
Intervention 5.6 ± 2.1 5.1 ± 2.6 5.3 ± 0.3 <.0005 .668 2.62 [1.74, 3.50]
Control 3.1 ± 2.9 2.3 ± 3.0 2.7 ± 0.3
Days missed any
medication doses
in past 7 days
Intervention .39 ± 1.2 .26 ± 1.0 0.3 ± 0.2 .030 .544 −0.51 [−0.97, −0.05]
Control .81 ± 1.6 .83 ± 1.4 0.8 ± 0.2
Days per week exercise Intervention 5.4 ± 1.8 4.5 ± 2.5 4.9 ± 0.3 <.0005 .230 1.66 [0.79, 2.53]
Control 3.4 ± 2.9 3.1 ± 2.5 3.3 ± 0.3
Physical Activity measured by ActiGraphc
Average daily
activity counts
Intervention 285,707 ± 152,860 306,648 ± 165,316 279,160 ± 19,821 .780 .693 8236 [−50,155; 66,628]
Control 251,265 ± 145,744 250,913 ± 275,411 270,924 ± 271,313
Average activity
kcals/kg/day
Intervention 2.2 ± 1.6 2.3 ± 1.9 2.08 ± 0.2 .773 .664 0.07 [−0.42, 0.56]
Control 1.8 ± 1.7 1.7 ± 1.8 2.01 ± 0.2
Average daily mins ≥
moderate intensity
activity
Intervention 5.8 ± 8.8 5.9 ± 10.8 4.81 ± 0.9 .897 .860 0.17 [−2.34, 2.71]
Control 3.3 ± 10.5 3.7 ± 7.1 4.65 ± 0.9




Intervention 1.7 ± 0.7 1.7 ± 0.6 1.70 ± 0.1 .282 .512 −0.09 [−0.26, 0.08]
Control 1.8 ± 0.5 1.8 ± 0.4 1.80 ± 0.1
Average daily sodium
intake (<1500 mg)
Intervention 3607.0 ± 1395.3 3748.7 ± 1586.2 3647.9 ± 157.3 .234 .818 −272.03 [−722.70, 178.65]
Control 3876.9 ± 1097.2 3926.6 ± 1279.3 3919.9 ± 163.5
a Observed means for the intervention group were based on n = 51, 51, and 50 cases for self-report measures, biomarkers, and actigraphy variables, respectively,
at month 3 and n = 50, 50, and 47 at month 6. For the control group, n = 47, 47, and 46 at month 3 and n = 46–47, 47, and 47 at month 6. The supplemental
analysis reported in the text that included baseline as a time point was based on all 99 cases having any actigraphy data at any time
b Estimated marginal means and statistical tests were obtained from a linear mixed model analysis, adjusted for baseline values of the outcome and specifying an
unstructured variance/covariance matrix
c Valid time needed to assess physical activity by ActiGraph was a minimum of 8 h of wear time or at least 2 valid days were required for calculation of
composites at each time point. The mean (± SD) days worn ranged from 5.9 (±1.4) to 6.3 (±1.2) days. Group mean hours worn ranged from 15.2 (±2.6) to
16.2 (±3.2)
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Table 3 Frequencies of self-management adherence by outcomes, group and time
Variable Group Baseline 3 Months 6 Months
Days missed any medication doses
in past 7 daysa
Intervention 0 days 86.3 % (44/51) 84.3 % (43/51) 86.0 % (43/50)
≥1 day 13.7 % (7/51) 15.7 % (8/51) 14.0 (7/50)
Control 0 days 81.6 % (40/49) 68.1 % (32/47) 68.1 % (32/47)
≥1 day 18.4 % (9/49) 31.9 % (15/47) 31.9 % (15/47)
χ2 = .130 (p = .719) b χ2 = 2.74 (p = .098) b χ2 = 3.47 (p = .060) b
Kept scheduled appointment with
primary care provider (within 30 days)
Intervention 100 % (51/51)
Control 97.9 % (46/47)
Fisher’s exact p = .295c
Days/wk follow low-sodium diet Intervention 0 days - 7.8 % (4/51) 14.0 % (7/50)
1 – 6 days - 35.3 % (18/51) 30.0 % (15/50)
7 days - 56.9 % (29/51) 56.0 % (28/50)
Control 0 days - 38.3 % (18/47) 55.3 % (26/47)
1 – 6 days - 40.4 % (19/47) 21.3 % (10/47)
7 days - 21.3 % (10/47) 23.4 % (11.47)
χ2 = 18.06 (p < .0005) χ2 = 19.28 (p < .0005)
Days/wk exercise Intervention 0 days - 2.0 % (1/51) 12.0 % (6/50)
1 – 6 days - 52.9 % (27/51) 50.0 % (25/50)
7 days - 45.1 % (23/51) 38.0 % (19/50)
Control 0 days - 23.4 % (11/47) 23.9 % (11/46)
1 – 6 days - 42.6 % (20/47) 58.7 % (27/46)
7 days - 34.0 % (16/47) 17.4 % (8/46)
χ2 = 10.49 (p = .005) χ2 = 5.87 (p = .053)
Days/wk weigh self Intervention 0 days - 13.7 % (7/51) 6.0 % (3/50)
1 – 6 days - 41.2 % (21/51) 56.0 % (28/50)
7 days - 45.1 % (23/51) 38.0 % (19/50)
Control 0 days - 46.8 % (22/47) 53.2 % (25/47)
1 – 6 days - 34.0 % (16/47) 31.9 % (15/47)
7 days - 19.1 % (9/47) 14.9 % (7/47)
χ2 = 14.42 (p = .001) χ2 = 26.69 (p < .0005)
≤1500 mg Na daily Intervention Not met 96.1 % (49/51) 98.0 % (49/50) 98.0 % (49/50)
Met 3.9 % (2/51) 2.0 % (1/51) 2.0 % (1/50)
Control Not met 100 % (49/49) 100 % (47/47) 100 % (47/47)
Met 0 % (0/49) 0 % (0/47) 0 % (0/47)
Fisher’s exact p = .495c Fisher’s exact p = 1.00c Fisher’s exact p = 1.00c
Exercise 7 days/wk (self-report) Intervention Not met - 54.9 % (28/51) 62.0 % (31/50)
Met - 45.1 % (23/51) 38.0 % (19/50)
Control Not met - 66.0 % (31/47) 82.6 % (38/46)
Met - 34.0 % (16/47) 17.4 % (8/46)
χ2 = 1.25 (p = .264) χ2 = 5.03 (p = .025)
≥120 mins/wk of moderate or
more intense activityd
Intervention Not met 91.8 % (45/49) 88.0 % (44/50) 91.5 % (43/47)
Met 8.2 % (4/49) 12.0 % (6/50) 8.5 % (4/47)
Control Not met 100 % (42/42) 95.7 % (44/46) 95.7 % (45/47)
Met 0 % (0/42) 4.3 % (2/46) 4.3 % (2/47)
Fisher’s exact p = .121c Fisher’s exact p = .271c Fisher’s exact p = .677c
aWith three categories, days with missed medication doses did not meet the assumptions of the χ2 test. Because very few patients missed 7 days at any time
point (1 in the intervention group at 3 months and at 6 months and 1 in the control group at 6 months), data from 1 to 6 days and 7 days were combined
bWith continuity correction for 2 × 2 table
cFisher’s exact test was used for 2 × 2 tables when assumptions of χ2 test were not met
dCriteria of recommended 150 min/wk considered met if 80 % (120 min) of target achieved
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90 days and at 180 days, the groups were not signifi-
cantly different (n = 12, 23.5 % and n = 12, 24.5 %,
respectively, at 90 days; n = 18, 35.3 % and n = 20, 40.8 %
at 180 days). A similar pattern was seen with ED visits
at 30 days (n = 6, 11.8 % and n = 1, 2.0 %); 90 days (n = 9,
17.6 %; and n = 5, 10.2 %); and 180 days (n = 12, 23.5 %
and n = 11, 22.4 %), but none of the differences were
significant.
Aim 3. To evaluate the mechanism of the patient
activation intervention, comparing the intervention
and UC groups on SM knowledge, self-efficacy for
self-management, patient activation, and SM strategies
at the end of intervention (3 months).
As shown in Table 4, the intervention group, on
average, showed significantly greater increases in self-
efficacy for heart failure SM (p = .034; d = .4), SM
strategies (p < .0005; d = 1.0), and patient activation
scores (p = .069; d = .3). No group differences were
found for SM knowledge, which changed approxi-
mately two points in each group.
Discussion
To our knowledge, this is the first efficacy trial of an
activation-enhancing in rural HF patients. Similar to
Shively’s and Hibbard’s studies [22, 23], the findings
demonstrate that the theory-based activation-enhancing
intervention was effective in increasing patient activation
level, leading to improved SM behaviors in rural HF
patients.
This study contributes to the field of SM in rural
HF population by adding the following evidence: 1)
understanding the effect of patient activation on SM
behaviors, 2) development of a conceptual framework
to guide the design and implementation of activation-
enhancing interventions to promote life-long SM ad-
herence; 3) using clinical biomarkers (BNP and urine
Na/Cr) to assess SM adherence; and 4) feasibility and
patients’ acceptance of home- based interventions to
improve SM behaviors.
Based on self-reported data, HF patients in the
PATCH intervention group had significant improvement
in activation scores and SM adherence in weighing
themselves daily, following a low-sodium diet and exer-
cising regularly. According to the objective measures
(i.e., physical activity measured by accelerometer and
daily sodium intake computed from urine sodium), how-
ever, the subjects from the intervention group did not
reach adherence threshold of sodium restriction and ex-
ercise intensity guidelines. Consequently, the reported
improvement in SM adherence and behaviors did not
improve clinical biomarkers or reduce readmissions.
Instead, the 30-day readmission rate was higher in the
intervention group than in the control group. Further-
more, the PATCH intervention had no impact on SM
knowledge at 3 months.
Similar to the rural HF populations in other studies
[24], our sample was predominantly white, retired, and
low income. However, our study did have more female
participants than have been reported in other studies.
During recruitment, we found women more willing than
men to participate in the study [15, 25, 26]. Field notes
indicated women were more likely to believe SM had
positive effects on their sustained independence and HF
symptom relief, felt more isolated and more often sought
social interactions with the research team, and had
greater interest in learning SM strategies. Consistent
with Dracup and Powell’s reports [5, 27], improved SM
adherence through education and training did not lead
to reduced readmissions in rural patients with mild to
moderate heart failure.







Mean change (SD) t-test
(p-value) a
Self-management knowledgeb 0–27 Intervention 51 21.1 (2.8) 51 23.1 (2.7) 2.0 (3.4) .337
Control 49 19.4 (3.0) 47 21.1 (2.5) 1.7 (2.6)
Self-efficacy for HF self-managementc 0–100 Intervention 51 44.9 (24.7) 51 59.7 (17.3) 14.8 (26.0) .034
Control 49 49.2 (22.9) 47 53.8 (24.0) 5.2 (25.5)
Patient activation
(PAM Rasch scaled scores) d
0–100 Intervention 51 57.3 (19.2) 50 69.1 (16.7) 11.7 (21.3) .069
Control 48 56.6 (18.6) 47 61.4 (18.2) 5.7 (18.5)
Self-management strategies (RSCB) e 0–145 Intervention 50 86.8 (19.3) 51 115.7 (19.6) 28.9 (23.0) <.0005
Control 49 91.9 (19.9) 47 97.6 (22.6) 5.6 (22.3)
aOne-tailed test of group difference in change from baseline to 3 months, equal variances not assumed
bPossible range for Self-management knowledge: 0-27
cPossible range for self-efficacy for HF self-management: 0-100
dPossible range for patient activation measure: 0-100
ePossible range for self-management strategies: 0-145
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There are several explanations for this deviation from
mainstream belief about the benefit of SM on HF out-
comes [28, 29]. First, low SM capability made it difficult
and sometimes impossible for some HF patients to
perform SM behaviors. SM capability is defined as the
capability to manage one’s illness-related symptoms, re-
quiring a competent level of cognition and adequate
health literacy [30]. Dracup and others [31] found low
health literacy and global cognition impairment were
prevalent in rural HF patients [31]. Second, the SM
guidelines, especially those related to sodium restriction
and exercise intensity, were found unachievable by many
participants [25]. Our data analysis showed that only
5 % HF patients fully adhered to the sodium restriction
guideline (≤1500 mg per day). BNP and sodium intake
are highly correlated [32]. Without fully complying with
the sodium restriction guideline, it would be highly un-
likely to observe significant changes in clinical bio-
markers (BNP or urine sodium/ creatinine ratio).
Similarly, only 6 % HF patients followed the physical ac-
tivity guideline (≥120 min per week moderate or above
intense activity). As a result, adherence behaviors didn’t
reach the threshold necessary to have affected the clin-
ical outcomes. Third, our patient sample had much
higher numbers of comorbidities compared to other HF
populations (8 vs. 3) [22], which could create competing
SM demands and further strain SM capability [33]. Last,
one explanation for the increased 30-day readmission in
the intervention group could be the poorer cardiac func-
tioning in the intervention grouppatients, which could
potentially increase risk of 30-day readmission [34].
However, even within class III patients only, readmission
rates were higher in the intervention group (28 %) than
in the usual care group (0 %). Another potential explan-
ation is the HF patients who received the PATCH inter-
vention might have had improved knowledge and skills
in recognizing warning signs of HF exacerbation, com-
municating their health concerns to their providers,
leading to appropriate hospitalization to prevent compli-
cations. Dracup also reported higher number of health-
care use in the intervention group. She suggested that
the HF patients in the intervention group were educated
to pay closer attention to their symptoms, leading to
subsequent hospitalizations [24]. Whether this patient-
initiated hospitalization improved the health outcomes
or not was not examined due to short-term follow up
(6 months) in our study.
Limitations and challenges
Several limitations exist in this study. First, the use of
convenience sampling affects the generalizability of the
findings to other HF populations. Second, the small
sample size might preclude the detection of significant
benefit brought by the intervention, although the small
effect sizes associated with the non-significant effects in-
dicate that this was unlikely. Third, participant recruit-
ment may have resulted in selection bias. Patients’
personal preferences, beliefs and experiences play a
major role in their decision whether to participate in a
clinical study. Often, those at risk (e.g., those with lower
literacy, more comorbidity, poorer health status, lack of
support, etc.) are likely to decline to enroll in behavioral
intervention trials [35]. If patients who enrolled in this
study were more confident and more actively engaged in
SM behaviors than patients who declined, the interven-
tion effects could have been diluted. Fourth, the inter-
vention was tailored to patients’ activation levels, but we
failed to recognize variations in patient SM capability.
Based on recommendations from patients, family, clini-
cians and our own experience, it is important to develop
a reliable and practice tool to assess SM capability, then
tailor the interventions to SM capability and patient acti-
vation level.
Future research direction
The 30-day readmission has been an important national
priority for HF patients given its impact on health out-
comes and healthcare cost [36]. However, it may not be
an accurate indicator of the effect of SM adherence. In
future studies, we plan to extend follow up time to see
the impact of patient-initiated hospitalization on long-
term health outcomes. In addition, we will also examine
the interaction between SM capability and activation
level, as well as their impact on SM adherence. The find-
ings may assist clinicians in identifying effective strat-
egies to support SM adherence.
Conclusion
In summary, results of PATCH trial are consistent with
previous trials; the activation-enhancing intervention
that improved SM behaviors and adherence without re-
ducing readmissions. Given the epidemic of heart failure
burdening on the health care system, we urgently need
to identify effective but feasible, sustainable strategies to
reduce healthcare utilization and improve quality of life
in rural HF populations.
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